RxDoctor Payments Data

James Stone, MD

Clinical Cardiac Electrophysiology · Tupelo, MSNPI 1417066226

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (46.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 77.7% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2019 at $33,471 and has fallen 83.5% since, to $5,537 in 2025.

$60,748in general payments, 2019–2025

Across 435 payments — averaging $139.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$47K
  • Biotronik Inc.$8K
  • Biosense Webster, Inc.$2K
  • Abbott$1K
  • Medtronic$247
  • Abiomed$219
  • plus $2K from 29 others
$1,526,836in research payments, 2019–2025

Across 629 payments — averaging $2427.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$868K
  • Medical Device Business Services, Inc.$409K
  • Abbott$112K
  • Medtronic$82K
  • Biotronik Inc.$51K
  • Novartis$3K
  • plus $1K from 1 others

What the payments were for

  • Consulting fees$13,40022%
  • Speaking & faculty fees$28,10046%
  • Travel & lodging$9,03615%
  • Food & beverage$10,16117%
  • Education$510%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical cardiac electrophysiology providers in Mississippito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$613,712
Medicare patients
1,608
Services billed
5,462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban803$668,205
XareltoRivaroxaban102$71,517
EntrestoSacubitril/Valsartan49$49,329
FarxigaDapagliflozin Propanediol29$25,455
MultaqDronedarone Hcl15$12,843
JardianceEmpagliflozin15$12,111
Propafenone Hcl272$9,883
Flecainide Acetate334$9,054
CorlanorIvabradine Hcl15$8,498
Metoprolol Succinate640$6,716
Dabigatran EtexilateDabigatran Etexilate Mesylate18$4,701
Amiodarone Hcl315$3,978
Digoxin133$2,364
Diltiazem 24hr Er (Cd)Diltiazem Hcl129$2,318
SotalolSotalol Hcl131$1,767

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$113$668,205803 claims
Johnson & JohnsonXarelto$12$71,517102 claims
NovartisEntresto$114$49,32949 claims
Sanofi-aventis U.S. LLCMultaq$104$12,84315 claims
Boehringer IngelheimJardiance$14$12,11115 claims
AmgenCorlanor$53$8,49815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical cardiac electrophysiology providers in Mississippion file to place this against a meaningful peer group, so we don't.

Other clinical cardiac electrophysiology in Tupelo

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →